Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib

被引：0
作者：
Spreafico, A
Gregorc, V
Ludovini, V
Pistola, L
Amoroso, M
Tofanetti, F
Compagnoni, A
Aondio, G
Tonato, M
Villa, E
机构：
[1] San Raffaele Sci Inst, Div Oncol, I-20132 Milan, Italy
[2] Monteluce Policlin, Dept Med Oncol, Perugia, Italy
[3] Ist Mario Negri, Biometry Unit, Dept Oncol, Milan, Italy
[4] Morigga Pelascini Hosp, Div Med Oncol, Gravedona, Italy
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80490-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S112 / S113
页数：2
相关论文
共 50 条
  • [21] Gefitinib in patients with non-small cell lung cancer (NSCLC): The Royal Marsden experience.
    Parton, M
    Maisey, N
    Banerjee, S
    Harper-Wynne, C
    Sumpter, K
    Ashley, S
    Eisen, T
    Obrien, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 641S - 641S
  • [22] Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib
    Chiu, Chao-Hua
    Shih, Yu-Ning
    Tsai, Chun-Ming
    Liou, Jia-Ling
    Chen, Yuh-Min
    Perng, Reury-Perng
    [J]. LUNG CANCER, 2007, 57 (02) : 213 - 221
  • [23] Factors predicting the efficacy of gefitinib in patients with advanced non-small cell lung cancer (NSCLC).
    Kishi, K
    Homma, S
    Miyamoto, A
    Sakamoto, S
    Motoi, N
    Yoshimura, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 644S - 644S
  • [24] CLINICAL EXPERIENCE USE GEFITINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH A MUTATION EGFR
    Vozniy, Eduard
    Popov, Anatoly
    Galkin, Michail
    Astrakhankina, Tamara
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1214 - S1214
  • [25] Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer
    Chen, Jing
    Gu, Runxia
    Wang, Qiong
    Dassarath, Meera
    Yin, Zhongyuan
    Yang, Kunyu
    Wu, Gang
    [J]. ONKOLOGIE, 2012, 35 (09): : 509 - 513
  • [26] Mutations in the epidermal growth factor receptor (EGFR): Retro-and prospective observations in non-small cell lung cancer (NSCLC) patients (pts) treated with gefitinib
    Nederlof, R
    Boerrigter, L
    Van 't Veer, L
    Baas, P
    van Zandwijk, N
    [J]. LUNG CANCER, 2005, 49 : S111 - S111
  • [27] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [28] Gefitinib in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-TK mutation - North Trent Cancer Network experience
    Nugent, L.
    Das, T.
    Mohanamurali, J.
    Danson, S. J.
    Fisher, P. M.
    Hatton, M. Q.
    Lee, C. E.
    Woll, P. J.
    [J]. LUNG CANCER, 2013, 79 : S9 - S9
  • [29] Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel
    Oscar Arrieta
    Pablo Anaya
    Vicente Morales-Oyarvide
    Laura Alejandra Ramírez-Tirado
    Ana C. Polanco
    [J]. The European Journal of Health Economics, 2016, 17 : 855 - 863
  • [30] Novel EGFR mutations in patients with non small cell lung cancer (NSCLC) and correlation T with sensitivity to gefitinib
    Voutsina, A.
    Koutsopoulos, A.
    Kalykaki, A.
    Souglakos, I.
    Pallis, A.
    Trypaki, M.
    Mavroudis, D.
    Georgoulias, V.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 250 - 251
12345